{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Change', 'Sections Changed', 'Based on \"Method 2\" described in \"Basic', 'Principles on Global Clinical Trials\" (Ministry', 'of Health, Japan, 2007), the probability of', 'observing a consistent trend across 2 regions', '(Japan vs. outside of Japan) is calculated.', 'Assume the true treatment effect is uniform', 'across the 2 regions and the natural logarithm', 'of HR is normally distributed. Per method of', 'Kawai (Kawai, 2008), 33 os events from', 'Japan, or 10% of total 330 os events, and', 'approximately 44 Japanese patients are', 'required for the primary analysis to yield a', 'probability of 84.6% to observe an HR <1', 'from both regions for the comparison of', 'REGN2810 (cemiplimab) versus the IC', 'chemotherapy options.', 'Subgroup analyses of patients from Japan are', 'Clinical Study Protocol Synopsis: Statistical', 'Plan', 'included.', 'Section 10.4.5.1 Primary Efficacy Analysis', 'Section 10.4.5.5 Subgroup Analyses', 'MedDRA Dictionary-Derived Preferred', 'Appendix 3 MedDRA Dictionary-Derived', 'Terms for Potential irAEs list updated as per', 'Preferred Terms for Potential irAEs', 'MedDRA version 20.1', 'Minor editorial changes', 'Throughout the protocol', 'Regeneron Pharmaceuticals, Inc.', 'Page 16 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Amendment 2', 'The following table outlines the changes made to the protocol and the affected sections.', 'Change', 'Sections Changed', 'Updated anti-drug antibody wording to', 'Section 4.3.2 Anti-Dug Antibody Variables', 'be consistent with current practice', 'Section 7.1.2 Footnotes for the Schedule of Events', 'Table for Screening and Treatment (footnote #12)', 'Revised exclusion criteria per request', 'Section 6.2.2 Exclusion Criteria (#6, 7, 19, and 20)', 'from the', 'Added a window between', 'Protocol Synopsis (Study Design)', 'randomization and start of treatment, to', 'Section 5.1 Study Description and Duration', 'try to provide some flexibility', 'Table 1 Schedule of Events (footnote reference #3)', 'Section 7.1.2 Footnotes for the Schedule of Events', 'Table for Screening and Treatment (added', 'footnote #3) (new)', 'Corrected length of study accrual and', 'Section 5.1.1 End of Study Definition', 'follow-up for consistency with other', 'sections', \"Clarified that some assessments didn't\", 'Table 1 Schedule of Events (footnote reference #6)', 'need to be performed at cycle 1/day 1 if', 'Section 7.1.2 Footnotes for the Schedule of Events', 'it was within 72 hours of screening, in', 'Table for Screening and Treatment (added', 'order to decrease site and patient burden', 'footnote #6) (new)', 'Reduced sampling of peripheral blood', 'Section 7.1.2 Footnotes for the Schedule of Events', 'mononuclear cells, to minimize blood', 'Table for Screening and Treatment (footnote #14', 'volume collection and to focus', '[was previously #11])', 'exploratory research in the earlier cycles', 'Corrected number of planned cycles to', 'Section 7.1.6 Option for Retreatment', 'be consistent across protocol', 'Revised wording to provide a window', 'Protocol Synopsis (Treatments)', 'for a drug-free period during irinotecan', 'Section 8.1.2.3 Irinotecan', 'dosing', 'Section 8.4.3 Irinotecan Dose Modifications', 'Added Eastern Cooperative Oncology', 'Section 8.8 Method of Treatment Assignment', 'Group (ECOG) performance status as a', 'stratification factor for randomization to', 'Regeneron Pharmaceuticals, Inc.', 'Page 17 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1. Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Change', 'Sections Changed', 'balance treatment assignment, per', 'request from the', 'The ECOG', 'performance status will not be included', 'in the primary analysis model for', 'efficacy.', 'Revised the alternate statistical', 'Section 10.1 Statistical Hypothesis', 'hypothesis at the request of', 'Updated sections to be consistent with', 'Section 6.2.2 Exclusion Criteria (#21, new)', 'the current protocol template', 'Section 14.3 Patient Confidentiality and Data', 'Protection (new section)', 'Made minor editorial changes', 'Section 5.1.1 End of Study Definition', 'Section 7.1 Schedule of Events', 'Section 7.1.2 Footnotes for the Schedule of Events', 'Table for Screening and Treatment', 'Section 7.1.5 Footnotes for the Schedule of Events', 'Table for Post-treatment Follow-up', 'Section 7.1.6 Option for Retreatment', 'Section 8.1.2 Control Group Treatments', \"(Investigator's Choice)\", 'Section 8.1.2.5 Vinorelbine', 'Section 8.5.1.1 Reasons for Permanent', 'Discontinuation of Study Treatment', 'Section 9.4.1 Adverse Events', 'Section 9.4.3 Other Events that Require', 'Accelerated Reporting to Sponsor', 'Section 9.4.4 Reporting Adverse Events Leading to', 'Withdrawal from the Study', 'Appendix 2 Recommended Dose Modification or', 'Discontinuation and Supportive Care Guidelines', 'for Specific Study Drug Related Adverse Events', 'Regeneron Pharmaceuticals, Inc.', 'Page 18 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}